Cell Membrane-Coated Oncolytic Adenovirus for Targeted Treatment of Glioblastoma

Area of Science:

• Oncolytic virotherapy
• Biotechnology
• Cancer research

Background:

• Oncolytic viruses show promise for glioblastoma (GBM) therapy.
• Challenges include the blood-brain barrier (BBB) and pre-existing immunity, hindering effective GBM treatment.

Purpose of the Study:

• To develop enhanced oncolytic adenoviruses for targeted GBM therapy.
• To overcome the BBB and pre-existing immunity against oncolytic viruses.

Main Methods:

• Prepared neural stem cell (NSC)- and GBM cell-membrane coated oncolytic adenoviruses (NCM-Ad and GCM-Ad).
• Engineered a dual-modified oncolytic adenovirus (A4/k37) for enhanced cytotoxicity.
• Evaluated infectivity, BBB crossing, immune evasion, and anti-tumor efficacy in vitro and in vivo models.

Main Results:

• NCM-Ad and GCM-Ad demonstrated improved GBM cell targeting and evasion of immune clearance.
• NCM-Ad effectively crossed the BBB and targeted tumor cells in vivo.
• NCM-A4/k37 exhibited significant tumor targeting and inhibition in an orthotopic GBM xenograft model.

Conclusions:

• Cell membrane-coated oncolytic adenoviruses offer a promising strategy for targeted GBM therapy.
• NCM-A4/k37 demonstrates potent anti-glioma capacity via intravenous administration.
• This approach provides a viable oncolytic virus-based therapeutic strategy for glioma.